Article Text

Download PDFPDF

Letter
Specific contributions of segmental transit times to gut microbiota composition
  1. Nele Steenackers1,
  2. Gwen Falony2,3,
  3. Patrick Augustijns4,
  4. Bart Van der Schueren1,5,
  5. Tim Vanuytsel6,7,
  6. Sara Vieira-Silva2,3,
  7. Lucas Wauters6,7,
  8. Jeroen Raes2,3,
  9. Christophe Matthys1,5
  1. 1 Department of Chronic Diseases and Metabolism, Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium
  2. 2 Department of Microbiology and Immunology, Rega institute, KU Leuven, Leuven, Belgium
  3. 3 Center for Microbiology, VIB, Leuven, Belgium
  4. 4 Department of Pharmaceutical and Pharmacological Sciences, Drug Delivery and Disposition, KU Leuven, Leuven, Belgium
  5. 5 Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium
  6. 6 Department of Chronic Diseases and Metabolism, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium
  7. 7 Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium
  1. Correspondence to Professor Christophe Matthys, Department of Chronic Diseases and Metabolism, Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium; christophe.matthys{at}uzleuven.be

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with great interest the study by Asnicar and colleagues, describing the exploration of gut microbiota composition in relation to gut transit time using the ‘blue dye’ method.1 In agreement with previous research, the authors provided convincing evidence that longer gut transit times are linked to increasing relative abundances of microbial species (ie, Akkermansia muciniphila, Bacteroides spp. and Alistipes spp.).1–3 However, despite practical advantages, the ‘blue dye’ method does not allow to distinguish between segmental transit times.

In a recent study, we investigated segmental transit time and passage-related variation in pressure and pH in 22 individuals (11 subjects with normal weight and 11 subjects with obesity) using a wireless motility capsule (SmartPill©).4 During capsule passage, participants were asked to collect a faecal sample. Samples were subjected to 16S rRNA gene amplicon sequencing according to Valles-Colomer et al.5 Associations between clinical and SmartPill© variables and faecal microbiota community variation were assessed using single and stepwise multivariate distance-based redundancy analyses (dbRDA). Next, we explored associations between the microbiome covariates identified and participants’ enterotypes using Kruskal-Wallis test with post-hoc pairwise Dunn’s test.6 Finally, correlations between relative abundances of genera and significant variables were assessed using Spearman correlations. Two-sided p values were adjusted for multiple testing using the Benjamini-Hochberg method.

As single explanatory variables, we identified a significant association between faecal community variation and body mass index (BMI), small-intestinal transit, small-intestinal pH and colonic transit (single dbRDA, p<0.05; figure 1A; table 1). However, only BMI and small-intestinal pH were observed to provide a significant, non-redundant contribution to genus-level microbiome diversification of 11.78% and 3.36%, respectively (stepwise dbRDA, false discovery rate (FDR) <0.05). All significant covariates of community variation were found to be associated with enterotype classification of faecal samples (Kruskal-Wallis test, FDR<0.05; figure 1B). More specifically, pairwise comparisons indicated that Ruminococcaceae (Rum)-enterotyped samples were associated with longer colonic transit than their Prevotella (Prev)-counterparts (Dunn, FDR=0.04). Additionally, individuals hosting a Bacteroides2 (Bact2)-enterotyped microbiota were characterised by a higher BMI (Dunn, FDR=0.02) and shorter small-intestinal transit (Dunn, FDR=0.02) than Bacteroides1 (Bact1)-carriers.

Figure 1

Faecal microbiota community variation among the SmartPill© cohort. (A) Visualisation of the faecal microbiota community variation among the SmartPill© cohort coloured per enterotype and projected on the FGFP background. Clinical and SmartPill© variables that have a significant explanatory power on community variation are depicted by arrows. The size of the arrow represents their effect size (single dbRDA). (B) Visualisation of the association between the significant covariates and enterotype classification of the faecal samples. (C) Visualisation of the association between the significant covariates and genera relative abundances. The colour gradient represents the Spearman Rho correlation coefficient, while marker size is linked to the significance level (large marker: FDR<0.05; small marker FDR>0.05. Bact1, Bacteroides1; Bact2, Bacteroides2; BMI, body mass index; CTT, colonic transit time; dbRDA, distance-based redundancy analyses; FDR, false discovery rate; FGFP, Flemish Gut Flora Project; Prev, Prevotella; Rum, Ruminococcaceae; SmartP, SmartPill©; SI pH, small-intestinal pH; SITT, small-intestinal transit time.

Table 1

Faecal microbiota community variation among the SmartPill© cohort

Sixteen genera were observed to be significantly associated with the covariates of microbiota community composition identified (Spearman, FDR<0.05; figure 1C). While relative abundances of 12 genera correlated with BMI, two were observed to be negatively associated with small-intestinal pH (Bacteroides, FDR=0.03 and Flavonifractor, FDR=0.03). While no taxa correlated significantly with small-intestinal transit, six genera were linked to colonic transit, five positively (Alistipes, FDR=0.03; Clostridium IV, FDR=0.003; Faecalicoccus, FDR=0.02; Methanobrevibacter, FDR=0.01; Phascolarctobacterium, FDR=0.03) and one negatively (Parasutterella, FDR=0.03). Among the former, Methanobrevibacter and Clostridium IV were additionally found to be associated with a lower BMI.

In conclusion, we observed that faecal microbiota community variation was linked to BMI and gastrointestinal (GI) conditions. In our cohort, a shorter small-intestinal transit was associated with the Bact2-enterotype, while a longer colonic transit was associated with the Rum-community type. Moreover, our findings revealed two genera to be related to small-intestinal pH and six genera to colonic transit. These findings are in agreement with the findings of Asnicar and colleagues, and prior publications.1 3 However, while they link gut microbiota to whole-gut transit, our findings provide insights into the link with segmental transit time. Moreover, these findings emphasise the importance of other GI conditions including small-intestinal pH.

Ethics statements

Patient consent for publication

Ethics approval

The study was conducted according to the Declaration of Helsinki and its later amendments; and was approved by the Ethics Committee for Research of the University Hospitals Leuven (S60930). Written informed consent was obtained from all participants prior to inclusion.

References

Footnotes

  • NS and GF are joint first authors.

  • JR and CM are joint senior authors.

  • Twitter @NeleSteenackers

  • Contributors NS helped in study conceptualisation, study design, data collection, data analysis, data interpretation and drafted the manuscript. GF helped in study conceptualisation, data analysis, data interpretation and revision of the manuscript. PA helped in study conceptualisation and revision of the manuscript. BVdS helped in study conceptualisation, study supervision and revision of the manuscript. TV helped in study conceptualisation, study supervision, data interpretation and revision of the manuscript. SVS helped in data analysis, data interpretation and revision of the manuscript. LW helped in data interpretation and revision of the manuscript. JR helped in revision of the manuscript. CM helped in study conceptualisation, study design, data interpretation and revision of the manuscript. NS and GF contributed equally as first authors to this paper. JR and CM contributed equally as last authors to this paper.

  • Funding The research was supported by a KU Leuven research grant [C32/17/046]. The purchase of the SmartPill© Equipment was supported by the Flanders Research Foundation [1520617N]. TV is supported by a senior clinical research fellowship of the Flanders Research Foundation [1830517N] and LW by a doctoral fellowship [1190619N] of the Flanders Research Foundation.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.